FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C.
20549
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2013
Commission File Number: 000-33295
3SBIO INC.
(Translation of
registrant’s name into English)
No. 3 A1, Road 10
Shenyang Economy &
Technology Development Zone
Shenyang 110027
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _______
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A
3SBio Inc. is furnishing under the cover of Form 6-K:
| Exhibit No. | Description |
| Exhibit 99.1 | Press release, dated May 1, 2013, regarding that 3SBio Inc. files annual report on form 20-F for Fiscal Year 2012. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 3, 2013
By: /s/ Dr. Jing Lou
Name: Dr. Jing Lou
Title: Chief Executive Officer
EXHIBIT INDEX
| Exhibit No. | Description |
| Exhibit 99.1 | Press release, dated May 1, 2013, regarding that 3SBio Inc. files annual report on form 20-F for Fiscal Year 2012. |
Exhibit 99.1
3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
SHENYANG, CHINA – May 1, 2013 – 3SBio Inc. (NASDAQ: SSRX) (“3SBio” or “the Company”), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has filed the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2012 with the U.S. Security and Exchange Commission on April 30, 2013. The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov or on the Investor Relations section of the Company’s website www.3sbio.com. Shareholders may also receive a hard copy of the annual report free of charge upon request.
About 3SBio Inc.
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol “SSRX”. Please see www.3SBio.com for more information.
Investor Contacts
Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86
24 2581-1820
ir@3SBio.com
Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com